What is the difference between Consensus-1 and Consensus-2 MCAS criteria?

Consensus-1 (Valent et al.) requires a documented rise in total serum tryptase by 20% + 2 ng/mL during an acute flare over baseline. However, over 70% of clinical MCAS patients never exhibit elevated tryptase because their mast cells primarily release other mediators (histamine, PGD2, leukotrienes, cytokines). Consensus-2 (Afrin, Molderings et al.) recognizes MCAS when episodic multi-system symptoms involve 2 or more organ systems, response to mast cell stabilizers is documented, and at least one validated urinary/plasma mediator is elevated.

Why is 24-hour urine testing so difficult for MCAS diagnosis?

Mast cell mediators (such as prostaglandin D2, 11-beta-PGF2alpha, and N-methylhistamine) are thermally unstable and degrade rapidly at room temperature. The 24-hour collection container must be kept strictly refrigerated or on ice throughout the entire collection period and during lab transport. If the sample warms above 4°C, false-negative results are common.

Why are POTS, hEDS, and MCAS so frequently seen together (The Trifecta)?

Mast cells reside in close proximity to unmyelinated C-nerve fibers and connective tissue extracellular matrices. In hypermobile Ehlers-Danlos Syndrome (hEDS), lax collagen allows greater mechanical shear stress on mast cell membranes, triggering degranulation. Degranulated mast cells release histamine and prostaglandins that dilate venous capacitance vessels, inducing the splanchnic and lower limb venous pooling that drives POTS.

Clinical Immunology Monograph & Diagnostic Screener

MCAS Diagnostic Criteria & Multi-System Checklist (Consensus-2)

A rigorous clinical evaluation of Mast Cell Activation Syndrome (MCAS) in Myalgic Encephalomyelitis (ME/CFS), Long COVID, and Postural Orthostatic Tachycardia Syndrome (POTS). Contrasting Consensus-1 vs. Consensus-2 criteria, urinary mediator collection protocols, and an interactive diagnostic decision engine.

Category: Mast Cell Biology & Neuro-Immunology | Author: About ME/CFS Medical Review Board | Updated: October 2026

1. The Pathophysiological Triad: MCAS, POTS & Hypermobility (hEDS)

In chronic neuro-immune illness, clinicians frequently observe an interconnected clinical triad: Mast Cell Activation Syndrome (MCAS), Postural Orthostatic Tachycardia Syndrome (POTS), and Hypermobile Ehlers-Danlos Syndrome (hEDS).

Mast cells are ancient innate immune sentinels situated at environmental interfaces (skin, respiratory mucosa, gastrointestinal tract, and the blood-brain barrier). When triggered by mechanical vibration, temperature shifts, viral remnants, or bioactive amines, mast cells release over 200 pre-formed and newly synthesized inflammatory mediators, including histamine, heparin, tryptase, leukotrienes, prostaglandin D₂, and tumor necrosis factor.

In post-viral ME/CFS and Long COVID cohorts, persistent microclots, autoantibodies, and subclinical viral reservoirs maintain mast cells in a state of chronic hyper-reactivity, mimicking multi-organ allergic anaphylactoid episodes without an IgE allergen trigger.

2. Consensus-1 vs. Consensus-2 Criteria: The Tryptase Debate

Diagnostic Framework	Core Requirement	Tryptase Threshold	Clinical Reality in ME/CFS
Consensus-1 (Valent et al. / AAAAI)	Recurrent severe anaphylaxis involving ≥ 2 organ systems + positive trial of mast cell blockers	(Baseline Tryptase × 1.20) + 2 ng/mL within 1–4 hours of acute flare	Extremely restrictive. Over 75% of ME/CFS and Long COVID patients have normal baseline and acute tryptase (< 11 ng/mL) because their mast cell degranulation is selective, predominantly releasing PGD₂, histamine, or cytokines rather than tryptase.
Consensus-2 (Afrin, Molderings et al.)	Episodic symptoms in ≥ 2 organ systems + clinical response to stabilizers + ≥ 1 elevated validated mediator	Tryptase is only one of multiple markers; recognizes urinary N-methylhistamine, 11-β-PGF_2α, or leukotriene E₄	Reflects the heterogeneous clinical phenotype observed in chronic fatigue, dysautonomia, and neuro-inflammation. Validates response to H1/H2 blockers and cromolyn sodium.

3. Interactive Consensus-2 Multi-System Screener & Tryptase Validator

Select all symptoms experienced chronically or during episodic flares across the 5 organ systems, and optionally enter your serum tryptase lab values to determine diagnostic probability under both consensus frameworks:

Consensus-2 Multi-Organ MCAS Diagnostic Screener

Diagnostic Decision Engine

1. Dermatological & Mucosal 0 Selected

Flushing (Face/Neck/Chest) Urticaria / Hives Pruritus / Severe Itching Dermatographia (Skin Welts) Angioedema (Lip/Eye Swelling)

2. Gastrointestinal 0 Selected

Abdominal Cramping / Pain Episodic Watery Diarrhea Severe Bloating / Early Satiety Nausea / Reflux (GERD) Multiple Food Chemical Intolerances

3. Cardiovascular & Autonomic 0 Selected

Tachycardia / Palpitations Sudden Hypotension / Lightheadedness Pre-Syncope or Syncope (Fainting) Blood Pressure Labile Swings

4. Respiratory & Naso-Ocular 0 Selected

Wheezing / Bronchospasm Throat Tightness / Sensation Chronic Nasal Congestion / Rhinitis Ocular Pruritus / Red Burning Eyes

5. Neurological & Systemic 0 Selected

Post-Flare Severe Brain Fog Migraine / Throbbing Headaches Episodic Anxiety / Adrenaline Surges Temperature Dysregulation / Shivers

Optional Serum Tryptase 20% + 2 Equation Check (ng/mL)

Baseline Tryptase

Acute Flare Tryptase (Within 4h)

Response to H1/H2 Blockers

0 Systems

Involved Organ Systems

Sub-Threshold

Consensus-2 Probability

8.24 ng/mL

Tryptase Cutoff ((Base × 1.2)+2)

Negative

Consensus-1 Status

Exportable multi-organ summary with Consensus-1/Consensus-2 evaluation for clinical intake.

4. The Chilled 24-Hour Urine Collection Protocol (Preventing False Negatives)

Because mast cell mediators are enzymatically unstable at ambient temperatures, up to 80% of routine commercial lab collections yield false-negative results due to improper handling:

Strict Specimen Integrity Guidelines

Chilled at All Times: The urine container must be kept inside a dedicated refrigerator or packed in ice water throughout the entire 24-hour collection period. Never allow the container to warm to room temperature.
Transport on Wet Ice: During transport to the reference laboratory (Quest, Labcorp, Mayo Clinic), transport the jug in an insulated cooler packed with ice packs. Instruct the lab technician to freeze the specimen immediately at -20°C.
The 4 Essential Mediators: (1) N-Methylhistamine (LC-MS/MS); (2) 11-β-Prostaglandin F_2α (11-β-PGF_2α); (3) Leukotriene E₄ (LTE₄); and (4) Urinary Free Histamine.

5. References & Scientific Citations

Afrin LB, et al. (2020). Diagnosis of mast cell activation syndrome: a proposal to consider by the American Academy of Allergy, Asthma & Immunology. Diagnosis, 8(1): 12-23. PMID: 32324159
Valent P, et al. (2019). Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. Journal of Allergy and Clinical Immunology: In Practice, 7(4): 1125-1133. PMID: 30738947
Weinstock LB, et al. (2021). Mast cell activation syndrome: a primer for the gastroenterologist. Digestive Diseases and Sciences, 66(4): 965-982. PMID: 33058031
Theoharides TC, et al. (2015). Mast cells and inflammation in chronic fatigue syndrome and fibromyalgia. Annals of Allergy, Asthma & Immunology, 114(4): 269-277.